Published in J Immunol on April 01, 2011
Pro-resolving lipid mediators are leads for resolution physiology. Nature (2014) 4.15
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol (2013) 1.80
Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci (2011) 1.60
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest (2012) 1.57
12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. J Exp Med (2014) 1.54
Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol (2013) 1.50
Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab (2013) 1.45
Resolution of acute inflammation in the lung. Annu Rev Physiol (2013) 1.42
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol (2015) 1.34
Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes (2012) 1.27
Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A (2013) 1.27
Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest (2015) 1.13
Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc Natl Acad Sci U S A (2012) 1.08
Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediators. J Exp Med (2013) 1.08
Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front Immunol (2012) 1.06
Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis. EMBO Mol Med (2013) 1.05
Lipid mediators in the resolution of inflammation. Cold Spring Harb Perspect Biol (2014) 1.04
Cutting-edge analysis of extracellular microparticles using ImageStream(X) imaging flow cytometry. Sci Rep (2014) 1.02
Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties. Mol Cell Proteomics (2013) 1.02
Wound repair: role of immune-epithelial interactions. Mucosal Immunol (2015) 1.00
Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol (2014) 0.95
Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. JCI Insight (2016) 0.88
Proresolving nanomedicines activate bone regeneration in periodontitis. J Dent Res (2014) 0.87
Proresolving lipid mediators and diabetic wound healing. Curr Opin Endocrinol Diabetes Obes (2012) 0.83
Stretching Impacts Inflammation Resolution in Connective Tissue. J Cell Physiol (2015) 0.82
Targeted Interleukin-10 Nanotherapeutics Developed with a Microfluidic Chip Enhance Resolution of Inflammation in Advanced Atherosclerosis. ACS Nano (2016) 0.79
Development of therapeutic polymeric nanoparticles for the resolution of inflammation. Adv Healthc Mater (2014) 0.79
Activation and resolution of periodontal inflammation and its systemic impact. Periodontol 2000 (2015) 0.79
Critical role of 5-lipoxygenase and heme oxygenase-1 in wound healing. J Invest Dermatol (2013) 0.79
Gene Expression of Proresolving Lipid Mediator Pathways Is Associated With Clinical Outcomes in Trauma Patients. Crit Care Med (2015) 0.78
Immune resolution mechanisms in inflammatory arthritis. Nat Rev Rheumatol (2017) 0.78
Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease. Proc Nutr Soc (2013) 0.78
Resolution mediator chemerin15 reprograms the wound microenvironment to promote repair and reduce scarring. Curr Biol (2014) 0.78
Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia. Am J Pathol (2016) 0.77
Aspirin-Triggered Resolvin D1-modified materials promote the accumulation of pro-regenerative immune cell subsets and enhance vascular remodeling. Acta Biomater (2017) 0.77
Obesity, immunomodulation and chronic kidney disease. Curr Opin Pharmacol (2013) 0.77
Arachidonic acid-derived signaling lipids and functions in impaired healing. Wound Repair Regen (2015) 0.77
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med (2017) 0.76
Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. Circ Res (2016) 0.76
17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiol Rep (2015) 0.76
Macrophage Proresolving Mediators-the When and Where. Microbiol Spectr (2016) 0.76
Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device. J Biomed Mater Res A (2016) 0.75
Resolvin D1 via prevention of ROS-mediated SHP2 inactivation protects endothelial adherens junction integrity and barrier function. Redox Biol (2017) 0.75
Nanoparticles: Is Toxicity a Concern? EJIFCC (2011) 0.75
Regulation of inflammation by lipid mediators in oral diseases. Oral Dis (2016) 0.75
Nonresolving inflammation. Cell (2010) 7.74
Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol (2007) 5.83
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science (2010) 4.22
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med (2008) 3.35
Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci U S A (2004) 2.43
Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32
Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. Blood (2004) 1.72
Temporomandibular disorders. N Engl J Med (2008) 1.64
Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood (2008) 1.61
A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. FASEB J (2004) 1.47
Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol (2007) 1.22
Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg Med Chem Lett (2008) 0.99
Measuring persistent temporomandibular joint nociception in rats and two mice strains. Physiol Behav (2010) 0.98
Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. Prostaglandins Leukot Essent Fatty Acids (2009) 0.93
Active intracellular transport of nanoparticles: opportunity or threat? ACS Nano (2007) 0.91
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Effect of iodine intake on thyroid diseases in China. N Engl J Med (2006) 5.46
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 5.08
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00
TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Role of the immune system in chronic pain. Nat Rev Neurosci (2005) 4.10
Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature (2012) 4.04
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44
Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med (2008) 3.35
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol (2006) 3.03
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol (2004) 2.86
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int (2012) 2.77
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol (2008) 2.68
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37
Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol (2006) 2.36
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet (2011) 2.32
Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17
Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J (2002) 2.13
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Resolvins and protectins in the termination program of acute inflammation. Trends Immunol (2007) 2.06
Resolution of inflammation: an integrated view. EMBO Mol Med (2013) 2.01
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96
The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96
Novel proresolving aspirin-triggered DHA pathway. Chem Biol (2011) 1.93
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med (2006) 1.90
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87
Epitaxial growth of single-domain graphene on hexagonal boron nitride. Nat Mater (2013) 1.84
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One (2010) 1.83
15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med (2009) 1.81
Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol (2013) 1.80
Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72
Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J (2011) 1.72
Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake. Am J Hematol (2008) 1.71
Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol (2010) 1.70
Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol (2011) 1.69
Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J Immunol (2005) 1.68
Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem (2013) 1.68
Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J (2007) 1.67
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67
International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev (2003) 1.66
Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood (2008) 1.66
Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity (2013) 1.64
Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood (2005) 1.62
Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood (2008) 1.61
Leukocyte antiadhesive actions of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood (2003) 1.60
Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci (2011) 1.60
Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci (2011) 1.58
The resolution of inflammation. Nat Rev Immunol (2012) 1.58
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest (2012) 1.57
Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem (2006) 1.55
Effects of sandy desertified land rehabilitation on soil carbon sequestration and aggregation in an arid region in China. J Environ Manage (2010) 1.54
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A (2002) 1.54
Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proc Natl Acad Sci U S A (2010) 1.53